Metropolis Healthcare Ltd (METROPOLIS)
₹583.90
Mkt cap
₹11,982 Cr
P/E ratio
57.60
P/B
8.00
Div yield
0.35%
ROE
13.60%
ROCE
17.80%
EPS (TTM)
₹10.14
Book value
₹73
52W range
422–596
Sector
Healthcare
Price history
Previous close
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
NSE METROPOLISBSE 542650
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−2.10% from high₹584
₹422+38.45% from low₹596
Current
₹583.90
Prev close
₹578.60
Day
+0.92%
Price performance
1D
+0.92%
1W
+0.28%
1M
+1.96%
3M
+11.34%
6M
+30.19%
1Y
+7.31%
YTD
+20.81%
Financials
Revenue, profit & margin
P/E ratio
57.6×
METROPOLIS is 36% above the sector median of 42.4×
METROPOLIS57.6×
Sector median42.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 277 | 308 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 | |
| Expenses | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 311 | 317 | 339 | |
| Operating Profit | 63 | 75 | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 | 95 | 108 | 111 | |
| OPM % | 23% | 24% | 22% | 24% | 25% | 26% | 22% | 18% | 23% | 25% | 23% | 25% | 25% | |
| Other Income | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 | -0 | 8 | 5 | |
| Interest | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 6 | |
| Depreciation | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 | 39 | 32 | |
| Profit before tax | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 | 70 | 78 | |
| Tax % | 26% | 26% | 26% | 28% | 25% | 24% | 26% | 19% | 26% | 26% | 26% | 27% | 27% | |
| Net Profit | 29 | 36 | 27 | 37 | 38 | 47 | 31 | 29 | 45 | 53 | 42 | 51 | 57 | |
| EPS in Rs | 1.41 | 1.73 | 1.33 | 1.78 | 1.85 | 2.27 | 1.53 | 1.41 | 2.17 | 2.54 | 2.00 | 2.46 | 2.73 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.33% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 4 Aug '26◦ |
| Earnings day | −1.33% |
| +1 day | −3.40% |
| +5 days | −5.49% |
| +15 days | −2.43% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202648.86%Promoter
Promoters48.86%
FIIs11.03%0.60
DIIs35.12%0.68
Public5.00%0.08
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹1,901.90 | 56.78 | 31,923 | 0.74% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| VIJAYA | ₹1,497.50 | 82.27 | 15,424 | 0.13% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| METROPOLIS | ₹577.75 | 57.56 | 11,982 | 0.35% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| THYROCARE | ₹573.15 | 50.47 | 9,123 | 1.63% | 51 | +34.06% | 240 | +24.34% | 35.38% |
| NEPHROPLUS | ₹710.85 | 83.99 | 7,148 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| KRSNAA | ₹564.05 | 18.49 | 1,830 | 0.35% | 16 | −19.12% | 211 | +19.95% | 12.70% |
| SURAKSHA | ₹338.90 | 49.30 | 1,765 | 0.15% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Median: 15 Co. | ₹522.00 | 42.38 | 1,306 | 0.13% | 14 | +28.77% | 157 | +19.52% | 23.07% |
Filings
Annual reports8
Concall transcripts79
TranscriptSep 2026PPTSep 2026RECSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTOct 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptDec 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Restructuring 7 Sep - MQSPL signed SSA and SHA with Medsource and Dr. Puneet; total investment about INR 1.26 crore.Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 7 SepAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 2 Sep - Transcript of Investors & Analyst Meet held on Thursday, August 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 27 Aug - Audio recording of Investors & Analyst Meet held on August 27, 2026 uploaded on company website.Disclosure Under Regulation 30 Of SEBI Listing Regulations 27 Aug - EQAS Division transferred to subsidiary MQSPL on slump sale for INR 1.25 crore, effective August 27, 2026.